SubHero Banner

Wegovy® (semaglutide) – New indication

March 8, 2024 - The FDA announced the approval of Novo Nordisk’s Wegovy (semaglutide), in combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease (CVD) and either obesity or overweight.

Download PDF